Background: During the first wave of the COVID-19 pandemic, a substantial number of Quebec hospitals were hit by hospital-acquired (HA) SARS-CoV-2 infections. Our objective was to assess whether mortality is higher in HA cases than in non-hospital-acquired (NHA) cases and determine the prevalence of HA-SARS-CoV-2 infection in our hospital.
Methods: This retrospective single-centre cohort study included all adults (≥ 18 yr) who had COVID-19, admitted to Hôpital Maisonneuve-Rosemont (Montréal, Canada) from Mar. 1 to June 30, 2020. We collected data on demographic characteristics, comorbidities, treatment, admission to the intensive care unit (ICU) and mechanical ventilation requirements from electronic health records. We adjudicated hospital acquisition based on the timing of symptom onset, and polymerase chain reaction testing for and exposures to SARS-CoV-2. To evaluate the association between HA-SARS-CoV-2 infection and in-hospital mortality, we computed a multivariable logistic regression analysis including known risk factors for death in patients with COVID-19 as covariates.
Results: Among 697 patients with SARS-CoV-2 infection, 253 (36.3%) were classified as HA. The mortality rate was higher in the HA group than in the NHA group (38.2% v. 26.4%, = 0.001), while the rates of ICU admission (8.3% v. 19.1%, = 0.001) and requirement for mechanical ventilation (3.6% v. 13.0%, = 0.001) were lower. Multivariable logistic regression analysis showed that HA-SARS-CoV-2 infection in patients younger than 75 years is an independent risk factor for death (odds ratio 2.78, 95% confidence interval 1.44-5.38).
Interpretation: Our results show that HA-SARS-CoV-2 infection in younger patients was associated with higher mortality. Future studies need to evaluate relevant patient-centred long-term outcomes in this population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812720 | PMC |
| http://dx.doi.org/10.9778/cmajo.20210055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity.
Hum Vaccin Immunother
December 2025
Department of Infectious Disease, Imperial College London, London, UK.
The COVID-19 pandemic highlighted the need for rapidly deployable, flexible vaccine platforms; particularly RNA which is now being explored for several other pathogens. DNA vaccines have potential advantages over RNA, including cost of manufacture, ease of storage and potentially lower reactogenicity. However, they have historically underperformed in large animals and human trials due to low immunogenicity.
View Article and Find Full Text PDFIntegration of Sequencing and Epidemiologic Data for Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in a Tertiary-Care Hospital.
Clin Infect Dis
February 2023
Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
Article Synopsis
- The study focuses on understanding the transmission of SARS-CoV-2 in a German hospital during the second and third pandemic waves, highlighting the burden on healthcare systems due to COVID-19.
- Researchers analyzed 284 samples from patients and staff, using full-length viral genome sequencing to identify infection sources and transmission patterns, while integrating various types of data for a comprehensive understanding.
- Findings indicate that while traditional epidemiological methods can identify most healthcare-associated infections, genomic surveillance is essential to uncover hidden transmission routes and improve response measures, thereby reducing infections despite high community transmission levels.
Outcomes of hospital-acquired SARS-CoV-2 infection in the Canadian first wave epicentre: a retrospective cohort study.
CMAJ Open
February 2022
Pulmonary Division (Melançon, Brosseau), Department of Medicine, Hôpital Maisonneuve-Rosemont, Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Est-de-l'Île-de-Montréal; Department of Medicine (Melançon, Brosseau, Bartoli, Wang), Faculty of Medicine, Université de Montréal; Critical Care Division (Brosseau, Wang), Internal Medicine Division (Bartoli), and Microbiology and Infectious Disease Division (Labbé, Lavallée, Marchand-Senécal), Department of Medicine, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal; Department of Microbiology, Infectious Diseases and Immunology (Labbé, Lavallée, Marchand-Senécal), Faculty of Medicine, Université de Montréal, Montréal, Que.
Background: During the first wave of the COVID-19 pandemic, a substantial number of Quebec hospitals were hit by hospital-acquired (HA) SARS-CoV-2 infections. Our objective was to assess whether mortality is higher in HA cases than in non-hospital-acquired (NHA) cases and determine the prevalence of HA-SARS-CoV-2 infection in our hospital.
Methods: This retrospective single-centre cohort study included all adults (≥ 18 yr) who had COVID-19, admitted to Hôpital Maisonneuve-Rosemont (Montréal, Canada) from Mar.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!